Suzuki Yoriyasu, Yeung Alan C, Yang Phillip C
Stanford University Medical Center, 300 Pasteur Drive, Room H-2157, Stanford, CA 94305-5233, USA.
Curr Cardiol Rep. 2007 Mar;9(1):45-50. doi: 10.1007/s11886-007-0009-6.
Stem cell therapy may provide an alternative therapeutic option for severe congestive heart failure (CHF). Despite the promise generated by this novel approach, precise in vivo monitoring of the transplanted cells and of subsequent myocardial restoration remains a challenge. The development of a sensitive, noninvasive imaging technology to track stem cells while assessing cardiac function is critical to monitor therapeutic efficacy. In vivo cardiovascular MRI of stem cells is an emerging application to identify, localize, and monitor stem cells while simultaneously evaluating the restoration of the injured myocardium following stem cell therapy. Furthermore, advances in scanner technology, pulse sequence design, and associated hardware have resulted in real-time guidance of catheter-based intervention to deliver cells accurately to the regions of myocardial injury. These capabilities have positioned MRI as the primary comprehensive imaging modality to monitor cell therapy.
干细胞疗法可能为严重充血性心力衰竭(CHF)提供一种替代性治疗选择。尽管这种新方法带来了希望,但对移植细胞以及随后心肌修复进行精确的体内监测仍然是一项挑战。开发一种灵敏的、非侵入性成像技术,以便在评估心脏功能的同时追踪干细胞,对于监测治疗效果至关重要。干细胞的体内心血管磁共振成像(MRI)是一种新兴应用,可用于识别、定位和监测干细胞,同时评估干细胞治疗后受损心肌的修复情况。此外,扫描技术、脉冲序列设计及相关硬件的进步,已实现基于导管介入的实时引导,从而将细胞准确输送至心肌损伤区域。这些能力使MRI成为监测细胞治疗的主要综合成像方式。